Op2Lysis

📍 Caen, France🗓 Founded 2016👥 8 employees💰 Last funded Jun 2018
Biotechnology Research🌐 op2lysis.com
Website LinkedIn
Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North America and Europe.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Belgium
1
Frequently asked questions
Who invested in Op2Lysis?
Op2Lysis has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Op2Lysis last raise funding?
The most recent investment in Op2Lysis recorded on gritt.io was in June 2018.
When was Op2Lysis founded?
Op2Lysis was founded in 2016.
What industry is Op2Lysis in?
Op2Lysis operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Op2Lysis based?
Op2Lysis is headquartered in Caen, France.